Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

71.75 -0.00 (-0.01%)
Streaming Delayed Price Updated: 4:15 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2023
 
Via Benzinga
Corcept Therapeutics Announces Final Results of Tender Offer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Analyst Ratings for Corcept Therapeutics
 
Via Benzinga
Analyst Expectations for Corcept Therapeutics's Future
 
Via Benzinga
Short Volatility Alert: Corcept Therapeutics
On Tuesday, shares of Corcept Therapeutics (NASDAQ: CORT) experienced volatile short activity. After the activity, the stock price went up +1.66% to $22.02. The overall sentiment for CORT has been... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
 
Via Benzinga
Corcept Therapeutics Announces Preliminary Results of Tender Offer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Return On Capital Employed Overview
  
Via Benzinga
Corcept Therapeutics Initiates CATALYST Clinical Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
 
Via Benzinga
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
From Corcept Therapeutics Incorporated
Via GlobeNewswire
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Our 7 Top Biotech Stock Picks for 2023
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Provides Miricorilant Clinical Development Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics's Earnings: A Preview
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
These 3 Stocks Are Winning the Bear Market -- Here's How
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies. 
Via The Motley Fool
7 Under-the-Radar Stocks With 100% Upside Potential
If you're looking for under-the-radar stocks in the current market environment, you're likely to find many imposters so tread carefully. 
Via InvestorPlace
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
Upgrades 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.